Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.83 +0.30 (+0.76%)
Delayed Quote Updated: 1:02 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗
This technology firm offers cloud-based data management and compliance tools for organizations using Microsoft 365 and other platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment ↗
The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently... 
Via Stocktwits
News headline image
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗
Via Chartmill
Why Is TEVA Stock Rising Pre-Market Today? ↗
Via Stocktwits
News headline image
CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗
The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 
Via Stocktwits
Topics Intellectual Property
News headline image
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
Via Finterra
Topics Economy World Trade
News headline image
Teva (TEVA) Q4 2024 Earnings Call Transcript ↗
Teva (TEVA) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Teva (TEVA) Q3 2024 Earnings Call Transcript ↗
Teva (TEVA) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗
Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗
Aytu BioPharma AYTU Q2 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗
The Invesco KBW Bank ETF tracks a sector-specific index of leading U.S. banking firms, emphasizing large and regional institutions. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Teva (TEVA) Q3 2025 Earnings Call Transcript ↗
Teva (TEVA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026
NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while... 
Via MarketMinute
Topics Earnings Economy Government
News headline image
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗
Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain... 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
My Top 10 Portfolio Holdings for 2026 ↗
This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come. 
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.